OncoResponse Adds Baxalta As Investor, Boosts Round To $12.5M

Houston-based biopharmaceuticals developer OncoResponse said Thursday that it has upped its Series A financing to a total of $12.5M, after securing a new investment from Baxalta. The Series A--which initially closed in October of 2015--was co-led by ARCH Venture Partners, Canaan Partners and MD Anderson, with William Marsh Rice University and Alexandria Real Estate Equities. The company said the new funding from Baxalta will go towards its ongoing efforts in the cancer immunotherapy area. OncoResponse is led by Clifford J. Stocks. More information »